AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Arbutus Biopharma Faces Patent Revocation in Europe
ByAinvest
Friday, Jan 16, 2026 10:03 am ET1min read
ABUS--
Arbutus Biopharma Corp has had its European patent EP 2279254 revoked by the European Patent Office. The company is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for chronic hepatitis B virus (HBV) infection. Its HBV product pipeline includes Imdusiran and AB-101, which target various steps in the HBV viral lifecycle. Arbutus Biopharma Corp's RNAi therapeutic and oral PD-L1 inhibitor product candidates aim to provide a functional cure for patients with cHBV infection.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet